Exelixis to evaluate cabozantinib and atezolizumab in solid tumors

28 February 2017
2019_biotech_test_vial_discovery_big

US biotech firm Exelixis (Nasdaq: EXEL) has joined forces with Roche (ROG: SIX) on a Phase Ib dose escalation study that will evaluate the safety and tolerability of its cabozantinib combined with a drug from the Swiss pharma giant.

Cabozantinib, Exelixis’ tyrosine kinase inhibitor (TKI), will be studied in combination with atezolizumab, Roche’s anti-PD-L1 immunotherapy, in patients with locally advanced or metastatic solid tumors. Enrollment is scheduled to begin mid-year 2017;Exelixis will be the sponsor of the trial, and Roche will provide atezolizumab.

This adds to a clinical development collaboration to evaluate Cabometyx (cabozantinib) with Opdivo (nivolumab), Bristol-Myers Squibb’s (NYSE: BMY) PD-1 immune checkpoint inhibitor, either alone or in combination with Yervoy (ipilimumab), in first-line renal cell carcinoma that Exelixis also announced yesterday.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology